AnaptysBio Inc (NASDAQ:ANAB) shares traded up 8.4% during trading on Friday . The stock traded as high as $89.89 and last traded at $88.82. 571,200 shares traded hands during mid-day trading, an increase of 170% from the average session volume of 211,584 shares. The stock had previously closed at $81.95.
Several research analysts recently commented on the stock. SunTrust Banks assumed coverage on shares of AnaptysBio in a research note on Wednesday, November 15th. They issued a “buy” rating and a $115.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a report on Tuesday, September 12th. Royal Bank Of Canada lifted their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, October 10th. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Wednesday, September 13th. Finally, Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Wednesday, October 11th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $84.78.
The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09.
Several hedge funds have recently made changes to their positions in ANAB. Citadel Advisors LLC bought a new stake in shares of AnaptysBio during the 3rd quarter valued at $20,406,000. Artal Group S.A. boosted its stake in AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after purchasing an additional 205,310 shares in the last quarter. VHCP Management II LLC bought a new position in AnaptysBio in the 3rd quarter worth about $5,856,000. JPMorgan Chase & Co. boosted its stake in AnaptysBio by 210.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after purchasing an additional 124,219 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in AnaptysBio in the 3rd quarter worth about $2,796,000. Hedge funds and other institutional investors own 75.48% of the company’s stock.
WARNING: “AnaptysBio (ANAB) Trading 8.4% Higher” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/12/08/anaptysbio-anab-trading-8-4-higher.html.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.